Freenome, Inc. operates as a biotechnology company focused on developing blood-based tests for early cancer detection using artificial intelligence and multiomics technology. The company develops and provides blood-based tests for early cancer detection, including a test for colorectal cancer screening. It offers a multiomics platform that combines computational biology, machine learning, and multiple data types to identify biomarkers and detect various cancers. The company conducts clinical research programs, such as the PREEMPT CRC, Sanderson, and Vallania studies, to validate and expand its cancer detection tests to multiple cancer types. It collaborates with healthcare organizations and partners to advance clinical studies and enhance its product portfolio, including an autoantibody platform with additional biomarkers, and provides patient stratification and monitoring solutions using its multiomics technology. The company was founded in 2014 and is based in Brisbane, California.
Frequently asked questions
What sector does Freenome, Inc. Common stock (FRNM) operate in?
Freenome, Inc. Common stock belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is Freenome, Inc. Common stock (FRNM) current stock price?
As of the latest data, Freenome, Inc. Common stock stock price is $13.81, with a previous close of $13.51. Freenome, Inc. Common stock gained $0.30 in the last trading session, representing a 2.22% increase.
What is Freenome, Inc. Common stock (FRNM) current market capitalization?
Freenome, Inc. Common stock market cap is approximately 1.47 billion.
What is Freenome, Inc. Common stock (FRNM) Earnings Per Share (EPS)?
The trailing EPS is -$2.32, and the forward EPS is -$2.59.
Does Freenome, Inc. Common stock (FRNM) pay dividends?
No. Freenome, Inc. Common stock does not pay a dividend.
What is Freenome, Inc. Common stock (FRNM) beta (volatility) score?
Freenome, Inc. Common stock has a beta of 0.348, indicating lower volatility than the overall market.
